PRESS RELEASE Dreieich, 4 October 2020. Bloomberg reported on 2 October 2020 that, according to informed circles, a private equity firm had approached the Chinese Creat Group Corp. to acquire a stake in Biotest AG. The consultations are at an early stage and there is no certainty that they will lead to a transaction. The company believes that thi [ … ]

PRESS RELEASE Biotest is one of the first plasma protein manufacturers to provide digital package leaflets for all products - The latest Biotest package leaflets are always available online - Simplified use for patients and medical professionals - Quicker access to current safety-related information for users of Biotest products Dreieich, 10 S [ … ]

PRESS RELEASE Biotest phase II study for the treatment of severe COVID-19 patients with trimodulin approved A clear reduction in mortality and in duration of ventilation support during intensive care stay is expected Worldwide unique, innovative plasma protein preparation for treatment of COVID-19 patients Expedited approval of trimodulin for C [ … ]

PRESS RELEASE Biotest achieves another important clinical milestone for IgG Next Generation Phase III study in Primary Immunodeficiency Disease (PID) successfully completed IgG Next Generation meets all clinical endpoints Results will serve as basis for worldwide approval Dreieich, 1 September 2020. Biotest AG today announced the completion of [ … ]

PRESS RELEASE Biotest increases sales in the first half of 2020 by over 20% to € 234.8 million - Adjusted EBIT increased to € 41.1 million - Two development projects regarding a therapy for COVID-19 infection started - Biotest Next Level expansion project running according to plan Dreieich, 13th August 2020. In the first half of financial yea [ … ]